Luke M. Beshar

Luke M. Beshar is a declared insider at 4 companies (board member); the most frequent names are Cambrex Corp, NPS Pharmaceuticals Inc and REGENXBIO Inc. Between 31 December 2005 and 30 June 2022, the trades on record add up to 144 filings.

Market trades split into 4 purchases (€186k) and 74 sales (€15.4M). The net balance comes to €15.2M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 12 share grants and 48 option exercises. Since January 2022: 3 purchases and no sales on the market.

Half of the purchases are above €40k and half below. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 5 July 2022, the filings show an open-market purchase worth €30k in Protara Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.